Phosphatase and tensin homolog (PTEN), which negatively regulates tumorigenic phosphatidylinositol (3,4,5)-trisphosphate (PIP3) signaling, is a commonly mutated tumor suppressor. The majority of cancer-associated PTEN mutations block its essential PIP3 phosphatase activity. However, there is a group of clinically identified PTEN mutations that maintain enzymatic activity, and it is unknown how these mutations contribute to tumor pathogenesis. Here, we show that these enzymatically competent PTEN mutants fail to translocate to the plasma membrane where PTEN converts PIP3 to PI(4,5)P2. Artificial membrane tethering of the PTEN mutants effectively restores tumor suppressor activity and represses excess PIP3 signaling in cells. Thus, our findings reveal a novel mechanism of tumorigenic PTEN deficiency.
INTRODUCTION
More than 1500 different mutations in the phosphatase and tensin homolog (PTEN) gene have been identified in different cancers (http://cancer.sanger.ac.uk). [1] [2] [3] [4] [5] [6] Approximately 40% of these are substitution missense mutations. These cancer-associated amino acid substitutions are distributed along the entire length of PTEN with the highest frequency in the lipid phosphatase catalytic residues, mutations of which abolish lipid phosphatase activity. However, there is a group of PTEN substitutions that maintain PTEN enzymatic activity, [7] [8] [9] and it is currently unknown how these mutations disrupt the tumor suppressor function of PTEN.
The membrane recruitment of PTEN is important for its lipid phosphatase function in phosphatidylinositol (3, 4, 5) -trisphosphate (PIP3) signaling. [10] [11] [12] [13] [14] [15] Membrane association of PTEN is negatively regulated by phosphorylation of the inhibitory C-terminal tail domain. When phosphorylated at four serine/threonine residues, the C-terminal tail binds to the membrane-binding regulatory interface and masks the membrane-binding domain containing the CBR3 loop of the C2 domain. 10, 11, 16 When the phosphorylation sites are mutated to alanine (termed PTEN A4 ), the C-terminal tail dissociates from the membrane-binding regulatory interface and promotes membrane recruitment of PTEN. 10, 16 Therefore, we hypothesized that the cancer-associated mutations that retain enzymatic activity might affect the membrane recruitment of PTEN. To test our hypothesis and determine whether the enzymatically competent mutants represent a new class of tumorigenic PTEN deficiency, we took advantage of PTEN A4 . Although functionally important, PTEN membrane association is difficult to analyze because a large number of PTEN molecules are present in the cytosol. 10, 11 The use of PTEN A4 dramatically decreases the cytosolic pool of PTEN and allows us to visualize membrane localization.
RESULTS AND DISCUSSION
We focused on a group of PTEN missense mutants selected by two criteria. We first chose mutations that do not inhibit phosphatase activity. [7] [8] [9] Among these, we further narrowed the choice down to four mutations, S10N, G20E, L42R and F90S, which are located in or near the membrane-binding regulatory interface (Figure 1a and Supplementary Table S1 ). 10 We first biochemically confirmed intact PIP3 phosphatase activity of these mutants using purified PTEN as we described previously. 10 Wild-type (WT) and mutant forms of human PTEN fused with green fluorescent protein (GFP) were expressed and immunopurified from Dictyostelium cells using agarose bead-coupled anti-GFP antibodies. PTEN S10N , PTEN G20E , PTEN L42R and PTEN F90S showed enzymatic activities indistinguishable from that of WT PTEN (Figure 1b ). Activity was completely abolished in the negative control PTEN C124S , which carries a substitution in the catalytic residue C124. Fluorescence microscopy of Dictyostelium cells (Figures 1c and d ) and the human cell line HEK293T (Figures 1f and g) expressing PTEN mutants fused to GFP showed that PTEN-GFP, PTEN S10N -GFP, PTEN G20E -GFP, PTEN L42R -GFP and PTEN F90S -GFP were mainly located in the cytosol and nucleus.
To determine whether the S10N, G20E, L42R and F90S mutations affect membrane association, we combined them with the A4 mutations. PTEN A4 -GFP was located at the plasma membrane in addition to the nucleus in Dictyostelium cells (Figures 1c and e ) and HEK293T cells (Figures 1f and h) , as previously reported. 10, 11 In contrast, PTEN S10N,A4 -GFP, PTEN G20E,A4 -GFP, PTEN L42R,A4 -GFP and PTEN F90S,A4 -GFP were unable to localize at the plasma membrane in both cell types ( Figures 1c and e for Dictyostelium, f and g for HEK293T). Their nuclear localization was increased, as expected from our previous study showing that dissociation of PTEN from the plasma membrane leads to accumulation in the nucleus. 10 The negative control Relative fluorescence intensity (Nuclear/cytoplasm) S10N,A4 G20E,A4 L42R,A4 F90S,A4 A4 CBR3(K5A),A4 S10N,A4 G20E,A4 L42R,A4 F90S,A4 A4 CBR3(K5A),A4 ** ** * * * S10N G20E L42R F90S WT S10N,A4 G20E,A4 L42R,A4 F90S,A4 A4 PTEN CBR3(K5A) -GFP, which carries mutations in the CBR3 loop of the membrane binding C2 domain, 10 showed cytosolic localization (Figures 1c-h) .
Because decreased stability of PTEN contributes to tumorigenesis, 17 we tested whether the S10N, G20E, L42R and F90S mutations affect the turnover of PTEN. Immunoblotting revealed similar levels of PTEN-GFP, PTEN S10N -GFP, PTEN G20E -GFP, PTEN L42R -GFP and PTEN F90S -GFP in HEK293T cells (Figures 2a) . In contrast, PTEN A4 -GFP, which has decreased stability, showed lower steady-state levels (Figure 2a ). Consistent with these results, PTEN-GFP, PTEN S10N -GFP, PTEN G20E -GFP, PTEN L42R -GFP and PTEN F90S -GFP had comparable half-lives in the presence of the protein synthesis inhibitor cycloheximide, whereas PTEN A4 -GFP showed a shorter half-life ( Figure 2b) . PTEN binds to another tumor suppressor, p53. 18, 19 We tested whether the four mutations defective in membrane localization affected this protein-protein interaction using co-immunoprecipitation. The results showed similar binding for WT and mutant PTEN to p53 (Supplementary Figure S1 ).
To probe the mechanism by which the S10N, G20E, L42R and F90S mutations inhibited membrane localization of PTEN, we performed an in vitro liposome-binding assay. Liposomes containing PC (70%), PS (20%), PI(4,5)P2 (5%) and PE-biotin (5%) were incubated with lysates of Dictyostelium cells expressing different PTEN-GFP proteins (Figures 2c and d) . Consistent with its cytoplasmic localization, WT PTEN-GFP bound only weakly to the liposomes. In contrast, PTEN A4 , which was enriched at the plasma membrane, showed approximately 10-fold higher association with the liposomes (Figures 2c and d) . The PTEN A4 -liposome interactions were reduced to the WT level by the mutations S10N, G20E, L42R and F90S, thus PTEN S10N,A4 -GFP, PTEN G20E,A4 -GFP, PTEN L42R,A4 -GFP and PTEN F90S,A4 -GFP only weakly interacted with the liposomes. Therefore, the decreased localization of the PTEN mutants at the plasma membrane likely results from their inability to bind to membrane phospholipids.
The C-terminal tail of PTEN binds to the membrane-binding regulatory interface and closes the protein conformation, physically limiting access of the membrane-binding site to the membrane (Figure 2e ). 10, 16 Mutations in the C-terminal phosphorylation sites in PTEN A4 release this inhibitory interaction (Figure 2e ). 11 To determine whether the S10N, G20E, L42R and F90S mutations restore this interaction in PTEN A4 , we performed an 'in trans' interaction assay and examined the binding of PTEN-GFP to a separate tail domain fused to FLAG after immunoprecipitation with anti-FLAG antibodies. As previously reported, 10, 11 although PTEN-GFP did not interact with PTEN 352-403 -FLAG, PTEN A4 -GFP showed a strong interaction (Figures 2f and g) . The S10N, G20E, L42R and F90S mutations did not affect the interaction of PTEN A4 -GFP with PTEN 352-403 -FLAG (Figures 2f and g) . A negative control, PTEN CBR3(K5A),A4 -GFP that carries mutations in the tail-binding CBR3 loop, 10 did not interact with PTEN 352-403 -FLAG. Therefore, S10N, G20E, L42R and F90S mutations do not stimulate interaction of the membrane-binding regulatory interface with the C-terminal tail.
To determine the function of PTEN S10N , PTEN G20E , PTEN L42R and PTEN F90S , we first investigated cell proliferation and starvationinduced differentiation of Dictyostelium cells. PTEN function is evolutionarily conserved in Dictyostelium and human cells. 10, 20, 21 The loss of PTEN in Dictyostelium causes defects in cell proliferation and differentiation into stress-resistant fruiting bodies under starvation conditions. 20 The expression of WT PTEN and PTEN A4 restored these phenotypes in Dictyostelium PTEN-null cells (Figures 3a and b ). However, PTEN S10N , PTEN G20E , PTEN L42R and PTEN F90S were unable to rescue the defects in the presence or absence of the A4 mutation (Figures 3a and b) . We then examined the role of PTEN in PIP3 signaling in HEK293T cells, in which PIP3 is overproduced, by measuring phosphorylation of AKT, a major downstream event of PIP3 signaling. 22 suppressive activity of PTEN A4 (Figures 3c and d) . Furthermore, we examined the effect of these cancer mutations on PIP3-dependent cell proliferation and migration in the MCF-10A PIK3CA cell line, which carries a constitutively active form of PI3Kα and has increased PIP3 signaling. 23, 24 When WT PTEN-GFP was expressed in MCF-10A PIK3CA cells, cell proliferation was significantly decreased approximately 2.5-fold compared with expression of the negative controls of GFP alone or the catalytic mutant PTEN C124S (Figure 3e ). S10N, G20E, L42R and F90S mutations completely blocked the ability of PTEN to decrease proliferation rates. Similarly, the function of PTEN in cell migration was significantly impaired by these four cancer mutations (Figure 3f ).
Finally, we tested whether artificial tethering of PTEN to the plasma membrane restored the function of PTEN S10N , PTEN G20E , PTEN L42R and PTEN F90S . For this, we added a myristoylation motif derived from the plasma membrane protein PKBR1 25 to the N terminus of PTEN. The lipid anchor motif effectively recruited WT and mutant PTEN to the plasma membrane as revealed by fluorescence microscopy (Figure 4a ). To assess the effect of membrane recruitment on the amount of PIP3 in the plasma membrane, we co-expressed a biosensor for PIP3, red fluorescent protein fused to the PIP3-binding PH domain from AKT1. 26 Bringing PTEN to the plasma membrane significantly improved the ability of PTEN S10N,A4 , PTEN G20E,A4 , PTEN L42R,A4 and PTEN F90S,A4 to remove PIP3 in the plasma membrane. These data further show that the primary defect of the PTEN cancer mutations can be traced to the defects in their membrane association.
In summary, we identified a new class of cancer-associated PTEN mutations that specifically inhibit the recruitment of PTEN to the plasma membrane as a result of impaired interactions with phospholipids. Our findings reveal the importance of membrane binding of PTEN in tumorigenic PIP3 signaling. As this class of mutations maintains normal PIP3 phosphatase activity and can be rescued by tethering to the plasma membrane, we envision that the pharmacologic promotion of membrane localization may be an effective strategy for anticancer therapy for this class of PTEN deficiency. According to the cBioportal and COSMIC databases, the four PTEN mutations analyzed in our study occur in~1% (11/1210, COSMIC) of all human cancer sequencing studies. Thus, associations with progression and prognosis cannot currently be assessed given the relatively small number of patients in these studies and the lack of follow-up information for most sequencing studies outside of the Cancer Genome Atlas. However, the fact that these mutations recur, albeit at low frequencies, substantiates the functional relevance. In addition, as stated in our Supplementary Table S1, these mutations appear to occur in a variety of cancer types. The cBioportal database suggests that these mutations are more frequent in breast, lung, brain and uterine cancers. Although the overall frequency is small, 1% of breast cancers is equivalent to~15 000 cases globally. This demonstrates the impact of our work; low-frequency mutations, which were previously of uncertain significance, now appear to be mutations of functional consequence. Thus, these mutations offer new insights into molecular mechanisms of cancer and possible new avenues for therapeutic intervention.
